Annual report
4323.TEDINET S100W4ZM
Period2024-04-01 → 2025-03-31
Filed2025-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 150
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥29.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥26.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥23.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥21.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥18.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥3.2bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥2.8bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.9bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.5bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.3bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.9bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.8bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.3bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥579m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥22.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥20.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥17.4bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥15.5bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥12.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.1bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥7.3bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥14.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥12.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.8bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥9.2bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥6.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥761m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥542m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥81m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥87m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥599m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥424m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥281m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥487m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥99.24 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.08 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥72.25 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.16 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥26.99 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.98 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥596.97 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥516.08 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥439.03 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥373.43 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥316.49 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 64.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.8% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.9% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 17.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.8% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.8% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.7% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,613 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,847 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,687 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 1,448 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 1,320 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥24.2bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥20.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥18.6bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥17.1bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥15.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥3.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥2.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥3.4bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.2bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.1bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.2bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.7bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.6bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.6bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1000m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥401m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥20.4bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥17.3bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥15.5bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥14.0bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥6.8bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥5.9bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥13.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥11.4bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥10.2bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥8.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥6.9bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.8bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥109.22 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.82 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.47 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.19 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.71 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥18.7 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥27 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥552.55 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥466.42 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥415.93 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥358.96 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥320.15 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 66.9% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.9% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 21.4% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.2% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.7% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 24,836,920 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,418,460 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,418,460 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 6,209,230 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,612,230 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,151 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 1,009 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 926 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 871 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 827 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 69
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥114m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥114m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥3.3bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥1.8bn |
| Global Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥93m |
| Global Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥76m |
| Global Businessreportable segment | employees | at 2025-03-31 | 275 pure |
| Global Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.8bn |
| Global Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.8bn |
| Global Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥79m |
| Global Businessreportable segment | segment assets | at 2025-03-31 | ¥2.4bn |
| Global Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥62m |
| Medical Big Data Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥49m |
| Medical Big Data Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥33m |
| Medical Big Data Businessreportable segment | employees | at 2025-03-31 | 176 pure |
| Medical Big Data Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Medical Big Data Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Medical Big Data Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥556,000 |
| Medical Big Data Businessreportable segment | segment assets | at 2025-03-31 | ¥2.8bn |
| Medical Big Data Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥662m |
| Package Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥53m |
| Package Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥37m |
| Package Businessreportable segment | employees | at 2025-03-31 | 267 pure |
| Package Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥5.9bn |
| Package Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥5.9bn |
| Package Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥4m |
| Package Businessreportable segment | segment assets | at 2025-03-31 | ¥4.7bn |
| Package Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥329m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥237m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥29.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥29.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥114m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥19.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥5.0bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥206m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥206m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥2.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.9bn |
| Global Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥44m |
| Global Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥56m |
| Global Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.4bn |
| Global Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.4bn |
| Global Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥70m |
| Global Businessreportable segment | segment assets | at 2024-03-31 | ¥2.4bn |
| Global Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥402m |
| Medical Big Data Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥60m |
| Medical Big Data Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥26m |
| Medical Big Data Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Medical Big Data Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Medical Big Data Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥3m |
| Medical Big Data Businessreportable segment | segment assets | at 2024-03-31 | ¥2.6bn |
| Medical Big Data Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥686m |
| Package Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥117m |
| Package Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥33m |
| Package Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Package Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Package Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6m |
| Package Businessreportable segment | segment assets | at 2024-03-31 | ¥4.0bn |
| Package Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥526m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥196m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥26.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥206m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥17.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥4.7bn |
| Medical Big Data Businessreportable segment | employees | at 2025-03-31 | 107 pure |
| Package Businessreportable segment | employees | at 2025-03-31 | 261 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,567
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments of loans receivable inv cf | CurrentYearDuration | -29614000 | JPY |
| Collection of loans receivable inv cf | Prior1YearDuration | 14547000 | JPY |
| Collection of loans receivable inv cf | CurrentYearDuration | 26382000 | JPY |
| Payments for guarantee deposits inv cf | Prior1YearDuration | -118551000 | JPY |
| Payments for guarantee deposits inv cf | CurrentYearDuration | -509279000 | JPY |
| Proceeds from collection of guarantee deposits inv cf | Prior1YearDuration | 24472000 | JPY |
| Proceeds from collection of guarantee deposits inv cf | CurrentYearDuration | 10646000 | JPY |
| Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YearDuration | 104478000 | JPY |
| Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYearDuration | － | JPY |
| Other net inv cf | Prior1YearDuration | 14686000 | JPY |
| Other net inv cf | CurrentYearDuration | － | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | -761475000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -1976668000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YearDuration | － | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYearDuration | 2167000 | JPY |
| Repayments of lease obligations fin cf | Prior1YearDuration | -24860000 | JPY |
| Repayments of lease obligations fin cf | CurrentYearDuration | -27566000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | － | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -12480000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -397228000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -558597000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | -244000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | － | JPY |
| Dividends paid to non controlling interests fin cf | Prior1YearDuration | -1752000 | JPY |
| Dividends paid to non controlling interests fin cf | CurrentYearDuration | -2868000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -424085000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -599345000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 19259000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 46164000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 722136000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -772292000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 6793050000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 7515186000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 7515186000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 6742894000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 15 | |
| Notes receivable trade | Prior1YearInstant | 39432000 | JPY |
| Notes receivable trade | CurrentYearInstant | 33709000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 5759505000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 7350612000 | JPY |
| Contract assets | Prior1YearInstant | 1376084000 | JPY |
| Contract assets | CurrentYearInstant | 1381469000 | JPY |
| Directors compensations sga | Prior1YearDuration | 346727000 | JPY |
| Directors compensations sga | CurrentYearDuration | 350030000 | JPY |
| Salaries and allowances sga | Prior1YearDuration | 1643873000 | JPY |
| Salaries and allowances sga | CurrentYearDuration | 1930032000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 220302000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 224981000 | JPY |
| Provision for directors bonuses sga | Prior1YearDuration | 136735000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration | 143673000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |